Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

The Underrated Risks of Tamoxifen Drug Interactions.

Hansten PD.

Eur J Drug Metab Pharmacokinet. 2018 Oct;43(5):495-508. doi: 10.1007/s13318-018-0475-9. Review.

2.

Recommendations for selecting drug-drug interactions for clinical decision support.

Tilson H, Hines LE, McEvoy G, Weinstein DM, Hansten PD, Matuszewski K, le Comte M, Higby-Baker S, Hanlon JT, Pezzullo L, Vieson K, Helwig AL, Huang SM, Perre A, Bates DW, Poikonen J, Wittie MA, Grizzle AJ, Brown M, Malone DC.

Am J Health Syst Pharm. 2016 Apr 15;73(8):576-85. doi: 10.2146/ajhp150565.

3.

Clinical Weighting of Drug-Drug Interactions in Hospitalized Elderly.

Juárez-Cedillo T, Martinez-Hernández C, Hernández-Constantino A, Garcia-Cruz JC, Avalos-Mejia AM, Sánchez-Hurtado LA, Islas Perez V, Hansten PD.

Basic Clin Pharmacol Toxicol. 2016 Apr;118(4):298-305. doi: 10.1111/bcpt.12495. Epub 2015 Nov 4.

4.

Is digoxin use for cardiovascular disease associated with risk of prostate cancer?

Wright JL, Hansten PD, Stanford JL.

Prostate. 2014 Jan;74(1):97-102. doi: 10.1002/pros.22733. Epub 2013 Sep 21.

5.

Careful scrutiny of the evidence for drug-drug interactions in clinical decision support systems is necessary.

Horn JR, Hansten PD.

J Manag Care Pharm. 2011 Nov;17(9):713. No abstract available.

6.

Comment: evaluation of contraindicated drug-drug interaction alerts in a hospital setting.

Horn JR, Hansten PD.

Ann Pharmacother. 2011 Jun;45(6):826; author reply 826-7. doi: 10.1345/aph.1P533a. Epub 2011 Jun 13. No abstract available.

PMID:
21672901
7.

Customizing clinical decision support to prevent excessive drug-drug interaction alerts.

Horn JR, Hansten PD, Osborn JD, Wareham P, Somani S.

Am J Health Syst Pharm. 2011 Apr 15;68(8):662-4. doi: 10.2146/ajhp100465. No abstract available.

PMID:
21460171
8.

Statin use and risk of prostate cancer: results from a population-based epidemiologic study.

Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL.

Am J Epidemiol. 2008 Aug 1;168(3):250-60. doi: 10.1093/aje/kwn141. Epub 2008 Jun 12.

9.

Proposal for a new tool to evaluate drug interaction cases.

Horn JR, Hansten PD, Chan LN.

Ann Pharmacother. 2007 Apr;41(4):674-80. Epub 2007 Mar 27.

PMID:
17389673
10.

Drug safety in patients with heart failure.

Juurlink DN, Hansten PD.

Arch Intern Med. 2005 Jan 10;165(1):118. No abstract available.

PMID:
15642888
11.

Identification of serious drug-drug interactions: results of the partnership to prevent drug-drug interactions.

Malone DC, Abarca J, Hansten PD, Grizzle AJ, Armstrong EP, Van Bergen RC, Duncan-Edgar BS, Solomon SL, Lipton RB.

J Am Pharm Assoc (2003). 2004 Mar-Apr;44(2):142-51.

PMID:
15098848
12.

Concordance of severity ratings provided in four drug interaction compendia.

Abarca J, Malone DC, Armstrong EP, Grizzle AJ, Hansten PD, Van Bergen RC, Lipton RB.

J Am Pharm Assoc (2003). 2004 Mar-Apr;44(2):136-41.

PMID:
15098847
13.

Drug interaction management.

Hansten PD.

Pharm World Sci. 2003 Jun;25(3):94-7.

PMID:
12840961
14.

Possible risks to patients receiving statins combined with other medications.

Hansten PD.

J Am Coll Cardiol. 2003 Feb 5;41(3):519-20. No abstract available.

15.

Performance of community pharmacy drug interaction software.

Hazlet TK, Lee TA, Hansten PD, Horn JR.

J Am Pharm Assoc (Wash). 2001 Mar-Apr;41(2):200-4.

PMID:
11297332
16.

ORCA: OpeRational ClassificAtion of drug interactions.

Hansten PD, Horn JR, Hazlet TK.

J Am Pharm Assoc (Wash). 2001 Mar-Apr;41(2):161-5. No abstract available.

PMID:
11297327
17.

Cyclosporine-drug interactions and the influence of patient age.

Lill J, Bauer LA, Horn JR, Hansten PD.

Am J Health Syst Pharm. 2000 Sep 1;57(17):1579-84.

PMID:
10984808
18.

Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer.

Farrow DC, Vaughan TL, Sweeney C, Gammon MD, Chow WH, Risch HA, Stanford JL, Hansten PD, Mayne ST, Schoenberg JB, Rotterdam H, Ahsan H, West AB, Dubrow R, Fraumeni JF Jr, Blot WJ.

Cancer Causes Control. 2000 Mar;11(3):231-8.

PMID:
10782657
19.

Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux.

Vaughan TL, Farrow DC, Hansten PD, Chow WH, Gammon MD, Risch HA, Stanford JL, Schoenberg JB, Mayne ST, Rotterdam H, Dubrow R, Ahsan H, West AB, Blot WJ, Fraumeni JF Jr.

Cancer Epidemiol Biomarkers Prev. 1998 Sep;7(9):749-56.

20.

Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer.

Farrow DC, Vaughan TL, Hansten PD, Stanford JL, Risch HA, Gammon MD, Chow WH, Dubrow R, Ahsan H, Mayne ST, Schoenberg JB, West AB, Rotterdam H, Fraumeni JF Jr, Blot WJ.

Cancer Epidemiol Biomarkers Prev. 1998 Feb;7(2):97-102.

21.

Drug interactions with antibacterial agents.

Horn JR, Hansten PD.

J Fam Pract. 1995 Jul;41(1):81-90. Review.

PMID:
7798069
22.

Nonsteroidal antiinflammatory drug discontinuation in patients with osteoarthritis.

Scholes D, Stergachis A, Penna PM, Normand EH, Hansten PD.

J Rheumatol. 1995 Apr;22(4):708-12.

PMID:
7791168
23.

Comment: pitfalls in reporting drug interactions.

Horn JR, Hansten PD.

Ann Pharmacother. 1993 Dec;27(12):1545-6. No abstract available.

PMID:
8305798
24.

Effects of H2-receptor antagonists on blood alcohol levels.

Hansten PD.

JAMA. 1992 May 13;267(18):2469; author reply 2470-1. No abstract available.

PMID:
1349357
25.

Drug interactions with antisecretory agents.

Hansten PD.

Aliment Pharmacol Ther. 1991;5 Suppl 1:121-8. Review.

PMID:
1679670
26.

Overview of the safety profile of the H2-receptor antagonists.

Hansten PD.

DICP. 1990 Nov;24(11 Suppl):S38-41.

PMID:
1980183
27.

Effect of metoclopramide on the absorption of an oral sustained-release quinidine product.

Yuen GJ, Hansten PD, Collins J.

Clin Pharm. 1987 Sep;6(9):722-5. No abstract available.

PMID:
3677569
28.

Metabolism of chlorpropamide.

Campbell RK, Hansten PD.

Diabetes Care. 1981 Mar-Apr;4(2):332. No abstract available.

PMID:
7215089
29.

Effect of antacid and ascorbic acid on serum salicylate concentration.

Hansten PD, Hayton WL.

J Clin Pharmacol. 1980 May-Jun;20(5-6 Pt 1):326-31.

PMID:
7400368
30.

Drug interaction exposures in an ambulatory Medicaid population.

Jinks MJ, Hansten PD, Hirschman JL.

Am J Hosp Pharm. 1979 Jul;36(7):923-7.

PMID:
382843
31.

Letter. Meperidine and combination oral contraceptives.

Hansten PD.

J Clin Pharmacol. 1975 Aug-Sep;15(8-9):640.

PMID:
1150914
32.

Cephalothin, gentamicin, colistin hazards.

Hansten PD.

JAMA. 1973 Mar 5;223(10):1158. No abstract available.

PMID:
4739382
33.

Drugs in the production of direct Coombs' test positivity.

Hansten PD.

Am J Hosp Pharm. 1971 Aug;28(8):629-32. No abstract available.

PMID:
5092593
34.

Oral contraceptives and glucose tolerance.

Hansten PD.

Ann Intern Med. 1970 Sep;73(3):492. No abstract available.

PMID:
5456004
35.

Retrieval and utilization of drug interaction information.

Hansten PD.

Am J Hosp Pharm. 1970 Jun;27(6):468-72. No abstract available.

PMID:
5446274
36.

Chlorpropamide and chloramphenicol.

Hansten PD.

Lancet. 1970 May 30;1(7657):1173. No abstract available.

PMID:
4192121
37.

Pharmacist's role in treatment.

Hansten PD.

N Engl J Med. 1969 Mar 6;280(10):565. No abstract available.

PMID:
5764468
38.

Role of the pharmacist in assessing the effects of drugs on clinical laboratory results.

Hansten PD, Owyang E.

Am J Hosp Pharm. 1968 Jun;25(6):298-301. No abstract available.

PMID:
5656775

Supplemental Content

Loading ...
Support Center